Categories: Health

Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference

EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce that it will be attending the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 12th to January 15th 2026.

Those wishing to meet with company management during the conference should reach out to investors@sanuwave.com to schedule a time.

About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

Sanuwave’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as may be required by applicable law.

Contact: investors@sanuwave.com 

GlobeNews Wire

Recent Posts

Calian Announces ATHORA to Accelerate Sovereign Defence Capability in Canada

OTTAWA, Ontario, May 25, 2026 (GLOBE NEWSWIRE) -- Calian Group Ltd. (TSX: CGY), a mission-critical…

3 hours ago

32/2026Trifork Group: Weekly report on share buyback

Schindellegi, Switzerland – 25 May 2026 Trifork Group AGCompany announcement no. 32/2026 Weekly report on…

3 hours ago

STMicroelectronics President and CEO Jean-Marc Chery to speak at BNP Paribas Exane CEO conference

STMicroelectronics President and CEO Jean-Marc Cheryto speak at BNP Paribas Exane CEO conference Geneva, May…

3 hours ago

XCMG Chairman Yang Dongsheng Joins Xuzhou Delegation on Economic and Trade Visits to Indonesia and Australia

XUZHOU, China, May 25, 2026 /PRNewswire/ -- Yang Dongsheng, Chairman of XCMG Group and XCMG Machinery,…

6 hours ago

ASIA PACIFIC’S LEADING DENTAL BODY CALLS FOR A PREVENTION-FIRST SHIFT IN ORAL HEALTH, BACKED BY NEW GLOBAL EVIDENCE

The Asia Pacific Dental Federation releases its first dentist-authored guidance on daily self-care — making…

9 hours ago

Calidi Biotherapeutics Provides Required NYSE American Disclosure

May 22, 2026 18:00 ET  | Source: Calidi Biotherapeutics, Inc SAN DIEGO, May 22, 2026…

16 hours ago